Thyroid Cancer Clinical Trials

138 recruitingLast updated: June 17, 2026

There are 138 actively recruiting thyroid cancer clinical trials across 27 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Thyroid Cancer Trials at a Glance

138 actively recruiting trials for thyroid cancer are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Not Applicable with 33 trials, with the heaviest enrollment activity in Houston, Boston, and Shanghai. Lead sponsors running thyroid cancer studies include Fudan University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and M.D. Anderson Cancer Center.

Browse thyroid cancer trials by phase

Treatments under study

About Thyroid Cancer Clinical Trials

Looking for clinical trials for Thyroid Cancer? There are currently 88 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Thyroid Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Thyroid Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 138 trials

Recruiting

Studies on Tumors of the Thyroid

Thyroid CancerPapillary Thyroid CancerFollicular Thyroid Cancer+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2,500 enrolled1 locationNCT00001160
Recruiting
Phase 4

The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response

surgical stress responseThyroid CancerThyroid and Parathyroid Surgery+1 more
University Hospital Dubrava48 enrolled1 locationNCT07600580
Recruiting

Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

Non-Medullary Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)500 enrolled1 locationNCT01109420
Recruiting
Not Applicable

Hereditary Risk Factors for Thyroid Cancer

Thyroid Cancer
Dana-Farber Cancer Institute250 enrolled1 locationNCT02747888
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled82 locationsNCT05538130
Recruiting
Phase 2

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

Metastic Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)54 enrolled1 locationNCT04927416
Recruiting

Natural History Study of Children and Adults With Medullary Thyroid Cancer

Medullary Thyroid Cancer
National Cancer Institute (NCI)259 enrolled1 locationNCT01660984
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

MelanomaNon-small Cell Lung CancerThyroid Cancer+2 more
Pfizer267 enrolled40 locationsNCT05355701
Recruiting
Phase 2

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled1 locationNCT03841617
Recruiting
Not Applicable

Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients

Thyroid Cancer
Tianjin Medical University Cancer Institute and Hospital150 enrolled1 locationNCT07634978
Recruiting
Not Applicable

Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

Prostate CancerThyroid CancerNeuroendocrine Tumors
Institut du Cancer de Montpellier - Val d'Aurelle350 enrolled4 locationsNCT04104529
Recruiting
Phase 2

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Neoadjuvant TreatmentThyroid Cancer
M.D. Anderson Cancer Center45 enrolled2 locationsNCT06959511
Recruiting
Phase 2Phase 3

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Primary HyperparathyroidismParathyroid CancerMultiple Endocrine Neoplasias+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)193 enrolled1 locationNCT07444723
Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting
Not Applicable

Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

Poorly Differentiated Thyroid CarcinomaAdvanced Thyroid CarcinomaRadioiodine-refractory Differentiated Thyroid Cancer
Zhejiang Provincial People's Hospital94 enrolled1 locationNCT07068542
Recruiting
Phase 2Phase 3

Trop2-targeted immunoPET Imaging of Solid Tumors

Liver CancerOvarian CancerCervical Cancer+11 more
RenJi Hospital400 enrolled1 locationNCT06851663
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaNon-small Cell Lung Cancer+8 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 1

Brodalumab in the Treatment of Immune-Related Adverse Events

Breast CancerLiver CancerEsophageal Cancer+15 more
Brian Henick, MD11 enrolled1 locationNCT06673329
Recruiting

Natural History Study of Parathyroid Disorders

Multiple Endocrine Neoplasia Type 1Primary HyperparathyroidismParathyroid Cancer+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)3,000 enrolled1 locationNCT04969926
Recruiting
Not Applicable

Ganoderma Spores Modulate the Gut-Brain Axis

Thyroid CancerDepression
Ling Zhiqiang300 enrolled1 locationNCT07524777